Plasma KIM-1 levels may be a useful, noninvasive biomarker for risk prognostication in metastatic RCC. Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with ...

The clinical efficacy of enfortumab vedotin plus pembrolizumab in real-world patients is compatible with that of the phase 3 EV-302 clinical trial. Treatment with enfortumab vedotin plus ...

Amid a rapidly evolving landscape in the treatment of muscle-invasive bladder cancer (MIBC), new findings presented at the ...

A recent study explored the association between rectal spacer use and the US county-level prevalence of erectile dysfunction.

According to investigators, there is no validated PSA-based endpoint to compare oncologic outcomes after radical prostatectomy and radiation therapy for localized prostate cancer.

Lutetium 177-PSMA-617 is an appropriate alternative to cabazitaxel in patients with metastatic castration-resistant prostate cancer, resulting in better progression-free survival. Greater survival ...

Adding stereotactic body radiotherapy to enzalutamide and ADT for oligometastatic castration-resistant prostate cancer prolongs radiographic progression-free survival. Adding metastasis-directed ...

Nadofaragene firadenovec appears effective in real-world patients with bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer ...

Investigators assessed whether MRI alone can identify all cases of Gleason grade group 2 or higher disease in patients on ...

Using an ARPI or taxane after 177Lu-PSMA-617 can produce a robust PSA response in patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu-PSMA-617) was approved in 2022 for patients with metastatic ...